Category: Health news

In a March 2024 interview, Elon Musk publicly disclosed that he has a prescription for ketamine to treat depression. The question of what medication is Elon Musk using has generated significant public interest and scrutiny, particularly regarding reports of additional substance use and conflicts with his companies' policies.

In September 2023, a U.S. Food and Drug Administration (FDA) advisory panel unanimously concluded that oral phenylephrine, an ingredient in over 260 products, is ineffective [1.2.4]. This article explores **why is phenylephrine being banned** from over-the-counter sales.

In 2023, a U.S. Food and Drug Administration (FDA) advisory committee unanimously voted that oral phenylephrine is ineffective, finally clarifying the core of the public health debate around what is the problem with phenylephrine. For decades, this ingredient has been a staple in over-the-counter (OTC) cold and allergy medications, yet robust modern clinical data fails to prove its efficacy for nasal congestion. The issue centers on its poor absorption and metabolism when taken orally, rendering it essentially useless for its intended purpose.

Available since 1946, Benadryl is a household name for allergy relief [1.2.3]. Recent news has led many to ask: 'Why are they taking Benadryl off the market?' The truth is, it isn't being removed, but a major change to its accessibility is under serious consideration due to safety concerns [1.4.2, 1.4.6].

In September 2023, a U.S. Food and Drug Administration (FDA) advisory committee unanimously concluded that oral phenylephrine, a key ingredient in hundreds of over-the-counter cold medicines, is ineffective at relieving nasal congestion [1.3.1, 1.3.3]. This article explains what nasal decongestant is being discontinued as a result and what consumers should use instead.

The U.S. Food and Drug Administration (FDA) officially determined that the shortage of tirzepatide injections was resolved in December 2024, after nearly two years of supply issues due to overwhelming demand. This definitive end to the **tirzepatide shortage** carries significant implications for patients, providers, and the compounding pharmacy industry.

In September 2023, a U.S. Food and Drug Administration (FDA) advisory committee unanimously concluded that oral phenylephrine is ineffective as a nasal decongestant [1.3.1, 1.3.2]. This article explores what decongestant is taken off shelves and what this means for consumers.

In September 2023, an FDA advisory committee unanimously concluded that oral phenylephrine, an active ingredient in many over-the-counter (OTC) cold remedies, is ineffective as a nasal decongestant. This decision has prompted many consumers to ask, 'Is the FDA pulling DayQuil?' while the agency proceeds with a formal proposal to remove the ingredient.

In September 2023, an FDA advisory panel unanimously voted that oral phenylephrine, an ingredient in products with about $1.8 billion in annual sales, is ineffective as a nasal decongestant [1.3.1, 1.2.2]. So, what cold medicine got banned or removed from shelves as a result?

In the United States, over 80 million people are prescribed medication for moderate to severe acute pain annually. Now, a new non-opioid painkiller, Journavx (suzetrigine), offers an answer to the question, "What is the new pain killer with no addiction?", by providing a potent, first-in-class alternative that works differently than traditional narcotics.